Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04487860 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of AS012 in Subjects With Non-segmental Vitiligo
A Phase 2 study of Non-segmental Vitiligo, sponsored by Ache Laboratorios Farmaceuticos S.A..
- Completed
- Registry status
- Phase 2
- Development phase
- 327
- Enrollment target
- 20
- Study locations
NCT04487860: Completed Phase 2 study of Non-segmental Vitiligo, sponsored by Ache Laboratorios Farmaceuticos S.A..
NCT04487860 is a Phase 2 study of Non-segmental Vitiligo that has completed, run by Ache Laboratorios Farmaceuticos S.A.. The registered enrollment target is 327 participants, above the 234-participant average among 9 other Non-segmental Vitiligo trials with a reported enrollment target (40% higher). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04487860, a Phase 2 study of Non-segmental Vitiligo, has completed, sponsored by Ache Laboratorios Farmaceuticos S.A..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 327 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a randomized, double blind, placebo-controlled, phase II study. The study will be performed as a multicenter, multinational study.
Primary Outcome
Vitiligo Area Scoring Index score: numeric score that can range from 0 to 100, with higher VASI scores denoting poorer the disease state
Conditions Studied
Interventions
- DRUG Placebo
- DRUG AS012
Study Locations (20)
Florida
- Sun Pharma Site 01 - Brandon
- Sun Pharma Site 06 - Fort Lauderdale
- Sun Pharma Site 04 - Miami
- Sun Pharma Site 05 - Miramar
- Sun Pharma Site 10 - Ormond Beach
California
- Sun Pharma Site 09 - Fremont
- Sun pharma site 30 - Los Angeles
Louisiana
- Sun Pharma Site 12 - Baton Rouge
- Sun Pharma Site 13 - New Orleans
Rhode Island
- Sun Pharma Site 29 - East Greenwich
- Sun Pharma Site 08 - Warwick
Texas
- Sun Pharma Site 03 - Dallas
- Sun Pharma Site 16 - Pflugerville
Arizona
- Sun Pharma Site 15 - Phoenix
Arkansas
- Sun Pharma Site 02 - Bryant
Indiana
- Sun Pharma Site 14 - West Lafayette
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 327 participants |
| Start Date | 2021-01-13 |
| Est. Completion | 2023-02-27 |
| Phase | Phase 2 |
What the finished NCT04487860 record still lists
NCT04487860 is an interventional study that assigns participants to a tested intervention. The registered 327 participants enrollment target is mid-sized for trials with a published cap, above the 234-participant average among 9 other Non-segmental Vitiligo trials with a reported enrollment target (40% higher).
The record links to 1 condition, with Non-segmental Vitiligo appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04487860 names 20 study sites across 12 states, led by Florida, California, Louisiana.
Frequently Asked Questions
What is clinical trial NCT04487860 about?
NCT04487860 is a clinical study titled "Efficacy and Safety of AS012 in Subjects With Non-segmental Vitiligo". This is a randomized, double blind, placebo-controlled, phase II study. The study will be performed as a multicenter, multinational study.
What is the current status of trial NCT04487860?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 327 participants. The study started on 2021-01-13. Estimated completion is 2023-02-27.
What conditions does trial NCT04487860 study?
This clinical trial studies the following conditions: Non-segmental Vitiligo.
What interventions are being tested in trial NCT04487860?
The interventions under investigation include: Placebo (DRUG), AS012 (DRUG).
Who is sponsoring clinical trial NCT04487860?
This trial is sponsored by Ache Laboratorios Farmaceuticos S.A., which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04487860 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Florida, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-segmental Vitiligo
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04487860's enrollment target sits among peer trials
327 4th of 9 higher than 6 of 9 other Non-segmental Vitiligo trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-segmental Vitiligo trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase 2 Study to Evaluate EI-001 in Non-segmental Vitiligo Patients
RECRUITING · Phase 2
-
A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
RECRUITING · Phase 2
-
An Open-label Single Center, Proof of Concept Study Evaluating the Efficacy of Roflumilast Foam 0.3% in Pediatric Patients With Non-Segmental Vitiligo (NSV)
RECRUITING · Phase 2
-
A Study of Zasocitinib in Adults With Nonsegmental Vitiligo
RECRUITING · Phase 2
-
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VYN201 Gel in Subjects With Non-segmental Vitiligo.
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04486378 · 327 participants · Phase 2
A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer
- NCT06370182 · 327 participants · NA
Safety and Effectiveness of Mechanical Thrombectomy Using the Anaconda ANA Funnel Catheter
- NCT05156983 · 328 participants · Phase 3
A Study of TAK-330 to Reverse the Effects of Factor Xa Inhibitors For Adults Needing Urgent Surgery
- NCT05380401 · 328 participants · NA
Metabolic Mechanisms Induced by Enteral DHA and ARA Supplementation in Preterm Infants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI